Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799705 | 0.90 | CCR6 (0.38) | CCR6PAX8ALDH1A1MAPTHPGD | |
| SCHEMBL6466553 | 0.85 | AOC3 (0.47) | AOC3SIGMAR1ALOX5 | |
| SCHEMBL7047948 | 0.83 | L3MBTL1 (0.43) | AOC3SIGMAR1ALOX5 | |
| SCHEMBL11210893 | 0.78 | AOC3 (0.46) | ALDH1A1AOC3SIGMAR1ALOX5 | |
| SCHEMBL25526046 | 0.76 | ALDH1A1 (0.49) | CCR6PAX8ALDH1A1MAPTHPGD | |
| SCHEMBL6181959 | 0.74 | CTSL (0.40) | CCR6PAX8 | |
| SCHEMBL13181407 | 0.74 | LTB4R (0.56) | ALDH1A1MAPTHPGD | |
| SCHEMBL4694106 | 0.74 | SIGMAR1 (0.46) | ALDH1A1MAPTHPGDABCB1SIGMAR1 | |
| SCHEMBL6183071 | 0.73 | ALDH1A1 (0.43) | CCR6PAX8ALDH1A1 | |
| SCHEMBL8736574 | 0.73 | ALOX5 (0.58) | ALDH1A1MAPTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CCR6 2563/4885PAX8 4751/4885ALDH1A1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.